Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP02
- Development stage
- Unknown
- Lead developer
- Avalyn Pharmaceuticals
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
AP02 is an investigational, inhaled formulation of nintedanib developed by Avalyn Pharma for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib is a small molecule inhibitor of multiple tyrosine kinases involved in the pathogenesis of lung fibrosis. By delivering nintedanib directly to the lungs via aerosol, AP02 aims to maximize therapeutic effects on diseased lung tissue while minimizing systemic exposure and associated side effects seen with oral formulations. Phase 1 clinical trials have demonstrated that AP02 is safe and well tolerated in both healthy volunteers and patients with IPF, showing a favorable safety profile compared to oral nintedanib. The drug is being advanced into Phase 2 clinical development for IPF[1][2][3][4][5][6].
- Brand names
- AP02AP-02AP 02
- Other names
- inhaled nintedanibnintedanib solution for inhalation
02
Targets
SFK (SRC family kinases)VEGFR (VEGFR family)FGFR (Fibroblast growth factor receptor)PDGFR (PDGFR family)
Beyond the preview
Go deeper on AP02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP02.